Clinical trial
An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
NCT03207672 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- August 18, 2017
- Completion date
- March 31, 2027
- Enrollment
- 140 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor